<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Uterine fibroids (leiomyomas): Epidemiology, clinical features, diagnosis, and natural history
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Uterine fibroids (leiomyomas): Epidemiology, clinical features, diagnosis, and natural history
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Uterine fibroids (leiomyomas): Epidemiology, clinical features, diagnosis, and natural history
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Elizabeth A Stewart, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shannon K Laughlin-Tommaso, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert L Barbieri, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alana Chakrabarti, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 03, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Uterine leiomyomas (also referred to as fibroids or myomas) are the most common pelvic neoplasm in females [
         <a href="#rid1">
          1,2
         </a>
         ]. They are noncancerous monoclonal tumors arising from the smooth muscle cells and fibroblasts of the myometrium. They arise in reproductive-age females and, when symptomatic, typically present with symptoms of abnormal uterine bleeding and/or pelvic pain/pressure. Uterine fibroids may also have reproductive effects (eg, infertility, adverse pregnancy outcomes).
        </p>
        <p>
         The epidemiology, diagnosis, and natural history of uterine leiomyomas are reviewed here. Leiomyoma histology and pathogenesis, management of uterine leiomyomas, differentiating leiomyomas from uterine sarcomas, and leiomyoma variants are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5478.html" rel="external">
          "Uterine fibroids (leiomyomas): Treatment overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5431.html" rel="external">
          "Uterine fibroids (leiomyomas): Histology and pathogenesis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14203.html" rel="external">
          "Uterine fibroids (leiomyomas): Differentiating fibroids from uterine sarcomas"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15676.html" rel="external">
          "Uterine fibroids (leiomyomas): Variants and smooth muscle tumors of uncertain malignant potential"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          TERMINOLOGY AND LOCATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Uterine fibroids are described according to their location in the uterus although many fibroids have more than one location designation  (
         <a class="graphic graphic_figure graphicRef53241" href="/z/d/graphic/53241.html" rel="external">
          figure 1
         </a>
         and
         <a class="graphic graphic_picture graphicRef80897 graphicRef59079" href="/z/d/graphic/80897.html" rel="external">
          picture 1A-B
         </a>
         ). The International Federation of Gynecology and Obstetrics (FIGO) classification system for fibroid location is as follows  (
         <a class="graphic graphic_figure graphicRef91085" href="/z/d/graphic/91085.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid3">
          3
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intramural myomas (FIGO type 3, 4, 5) – These leiomyomas are located within the uterine wall. They may enlarge sufficiently to distort the uterine cavity or serosal surface. Some fibroids may be transmural and extend from the serosal to the mucosal surface.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Submucosal myomas (FIGO type 0, 1, 2) – These leiomyomas derive from myometrial cells just below the endometrium (lining of the uterine cavity). These neoplasms protrude into the uterine cavity. The extent of this protrusion is described by the FIGO/European Society of Hysteroscopy classification system and is clinically relevant for predicting outcomes of hysteroscopic myomectomy  (
         <a class="graphic graphic_figure graphicRef59668" href="/z/d/graphic/59668.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid4">
          4
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/3314.html" rel="external">
          "Uterine fibroids (leiomyomas): Hysteroscopic myomectomy", section on 'Leiomyoma characteristics'
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Type 0 – Completely within the endometrial cavity
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Type 1 – Extend less than 50 percent into the myometrium
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Type 2 – Extend 50 percent or more within the myometrium
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Subserosal myomas (FIGO type 6, 7) – These leiomyomas originate from the myometrium at the serosal surface of the uterus. They may have a broad or pedunculated base  (
         <a class="graphic graphic_diagnosticimage graphicRef63661" href="/z/d/graphic/63661.html" rel="external">
          image 1
         </a>
         ) and may be intraligamentary (ie, extending between the folds of the broad ligament).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cervical myomas (FIGO type 8) – These leiomyomas are located in the cervix rather than the uterine corpus.
        </p>
        <p>
        </p>
        <p>
         While conceptually straightforward, a study attempting to validate the FIGO classification system found significant disagreement on classification among experts [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PREVALENCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Uterine leiomyomas are the most common pelvic tumor in females [
         <a href="#rid1">
          1,2,6
         </a>
         ]. Incidence is difficult to determine since there are few longitudinal studies [
         <a href="#rid7">
          7
         </a>
         ]. In addition, the actual prevalence is unknown since studies have been conducted mainly in symptomatic patients or following hysterectomy. Representative studies include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the Nurses' Health Study II, a large prospective study in the United States, over 95,000 females ages 25 to 44 were followed from 1989 to 1993 [
         <a href="#rid8">
          8
         </a>
         ]. The age-standardized incidence rates of fibroids confirmed by ultrasound or hysterectomy were 9.2 per 1000 woman-years overall, 30.6 for Black females, and 8.9 for White females. Overall incidences by age group were: 25 to 29 (3.3 per 1000 woman-years), 30 to 34 (6.8), 35 to 39 (10.3), and 40 to 44 (16.0).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a population-based study of an urban health plan in Washington, DC, 1364 females ages 35 to 49 years were randomly selected and assessed by survey and/or ultrasound [
         <a href="#rid1">
          1
         </a>
         ]. Newly detected fibroids were present in 59 percent of Black females and 43 percent of White females; for females in their late 40s, the estimated frequency of fibroids was &gt;80 percent and near 70 percent for Black and White females, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A cross-sectional study in Europe of 1756 patients with fibroid-related symptoms found myomas in 12 to 24 percent [
         <a href="#rid9">
          9
         </a>
         ]. Myomas are clinically apparent in approximately 12 to 25 percent of reproductive-age females and noted on pathologic examination in approximately 80 percent of surgically excised uteri [
         <a href="#rid9">
          9,10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A detailed pathologic study of 100 hysterectomy specimens found myomas in 77 percent of uterine specimens [
         <a href="#rid10">
          10
         </a>
         ]. Most patients had multiple myomas, with an average of 7.6 fibroids.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An ultrasound screening study of asymptomatic females aged 18 to 30 found a prevalence of 26 percent in Black females and 7 percent in White females [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The incidence and prevalence of leiomyomas increase with age during the reproductive years [
         <a href="#rid1">
          1,8,12
         </a>
         ]. In an ultrasound screening study examining the incidence of fibroids in Black females, a high-risk group, age-specific incidence rates (cases/1000 person-years) for patients &lt;30 years, 30 to 34 years, and 35 to 39 years were 49.7, 55.2, and 58.2, respectively; 23 percent of the study participants were excluded for having fibroids at the initial intake examination [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         Leiomyomas have not been described in prepubertal girls, but they are occasionally noted in adolescents. Most, but not all, patients have shrinkage of leiomyomas after menopause.
        </p>
        <p class="headingAnchor" id="H30312561">
         <span class="h1">
          RISK FACTORS
         </span>
        </p>
        <p class="headingAnchor" id="H998155295">
         <span class="h2">
          Reproductive and endocrine factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         The epidemiology of leiomyomas parallels the ontogeny and life cycle changes of the reproductive hormones estrogen and progesterone. Although the growth of fibroids is responsive to gonadal steroids, these hormones are not necessarily responsible for the genesis of the tumors. (See
         <a class="medical medical_review" href="/z/d/html/5431.html" rel="external">
          "Uterine fibroids (leiomyomas): Histology and pathogenesis", section on 'Steroid hormones'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3773497408">
         <span class="h3">
          Parity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Parity (having one or more pregnancies extending beyond 20 weeks of gestation) decreases the chance of fibroid formation [
         <a href="#rid13">
          13-15
         </a>
         ]. There is a suggestion that additional pregnancies further decrease the risk [
         <a href="#rid7">
          7,15,16
         </a>
         ]. In some cohorts, older age at first birth was also associated with a decreased risk compared with younger age at first birth and a longer interval since last birth with an increased risk [
         <a href="#rid7">
          7,16
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H30312671">
         <span class="h3">
          Early menarche
         </span>
         <span class="headingEndMark">
          —
         </span>
         Early menarche (&lt;10 years old) is associated with an increased risk of developing fibroids. This may account for the early onset of disease in Black patients, in whom menarche is generally earlier than in White patients [
         <a href="#rid16">
          16-20
         </a>
         ]. In White patients, a specific polymorphism in the transcription factor
         <em>
          HMGA2,
         </em>
         one of the key driver mutations of leiomyomas, appears to be linked to both uterine leiomyomas and shorter adult height, suggesting that early menarche may be a key influence [
         <a href="#rid18">
          18
         </a>
         ]. Menarche is associated with increase of estradiol to postpubertal levels which can plausibly lead both to increased fibroid growth and early fusion of the long bone epiphyses leading to decreased height.
        </p>
        <p class="headingAnchor" id="H5291214">
         <span class="h3">
          Hormonal contraception
         </span>
         <span class="headingEndMark">
          —
         </span>
         Use of standard or lower dose oral contraceptives (OCs; ≤35 mcg ethinyl estradiol/day) does not appear to cause fibroids to grow; therefore, administration of these drugs is not contraindicated in patients with fibroids [
         <a href="#rid13">
          13,16,21-23
         </a>
         ]. One possible exception was reported by the Nurses' Health Study, which suggested OC use was associated with an increased risk of leiomyomas in patients with early exposure to OCs (13 to 16 years old) [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         Long-acting progestin-only contraceptives (eg, depot medroxyprogesterone) appear to protect against development of leiomyomas [
         <a href="#rid16">
          16,23-25
         </a>
         ]. However, studies of postpartum fibroid regression suggest that these agents inhibit fibroid regression specifically when used in the postpartum period [
         <a href="#rid26">
          26
         </a>
         ]. Studies investigating the symptomatic control of bleeding by progestin intrauterine devices have shown small decreases in fibroid or uterine size [
         <a href="#rid27">
          27,28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H717171242">
         <span class="h3">
          Other endocrine factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prenatal exposure to diethylstilbestrol is associated with an increased risk of fibroids, supporting the role of early hormonal exposure in pathogenesis [
         <a href="#rid29">
          29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5427.html" rel="external">
          "Outcome and follow-up of diethylstilbestrol (DES) exposed individuals"
         </a>
         .)
        </p>
        <p>
         There are no credible cases of uterine enlargement with ovulation induction [
         <a href="#rid30">
          30,31
         </a>
         ]. A nationwide cohort study of patients undergoing in vitro fertilization reported a decrease in risk of fibroids for patients with a higher response to ovarian stimulation than those with a normal response [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p>
         Environmental exposures such as phthalates, polychlorinated biphenyl, and bisphenol A appear to be linked to an increased risk of fibroids, possibly through endocrine disruption [
         <a href="#rid33">
          33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5447.html" rel="external">
          "Overview of occupational and environmental risks to reproduction in females"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5286725">
         <span class="h2">
          Obesity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most studies show a relationship between fibroids and increasing body mass index (BMI); however, a relationship with increased BMI, weight gain as an adult, or body fat varies across studies [
         <a href="#rid21">
          21,34-38
         </a>
         ]. The relationship is complex and is likely modified by other factors, such as parity, and may be more related to change in body habitus as an adult.
        </p>
        <p class="headingAnchor" id="H1995369136">
         <span class="h2">
          Diet, alcohol, and smoking
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diet
         </strong>
         – Studies regarding dietary effects on fibroids include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Significant consumption of beef and other reds meats (1.7-fold) or ham (1.3-fold) is associated with an increased relative risk of fibroids and consumption of green vegetables (0.5-fold) and fruit (especially citrus fruit) with a decreased risk [
         <a href="#rid39">
          39,40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         One report suggested that consumption of dairy products, but not soy products, is inversely related to fibroid risk in Black patients [
         <a href="#rid41">
          41
         </a>
         ]. There was no confounding effect of soy consumption, which is often a substitute for dairy products in lactose intolerant patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Increases in dietary glycemic index or load are associated with a small increase in fibroid risk in some patients [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         While overall fat intake does not appear to be related, dietary consumption of marine omega-3 fatty acids (eg, docosahexaenoic acid or environmental pollutants associated with this type of fat) may be associated with an increase in fibroid risk in some patients [
         <a href="#rid43">
          43,44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Dietary consumption of carotenoids is not associated with a change in risk for uterine leiomyoma [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Dietary vitamin A from animal sources may also be associated with decreased fibroid risk [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         There is increasing evidence that vitamin D deficiency or insufficiency, which is more prevalent among Black patients, is linked to fibroid risk [
         <a href="#rid46">
          46,47
         </a>
         ]. The major source of vitamin D is from synthesis from a prohormone when sunlight hits the skin, and this is inhibited by the higher levels of melanin in darker skin. This relationship is especially interesting because it is a biologically plausible explanation for the increased fibroid risk in Black patients that lends itself to prevention trials.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Caffeine consumption is generally not a risk factor for fibroids, except for weak associations in patients under age 35 with high consumption of coffee or caffeine intake [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Alcohol
         </strong>
         – Consumption of alcohol, especially beer, appears to be associated with an increased risk of developing fibroids [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Smoking
         </strong>
         – Some studies have shown an association between smoking and a decreased risk of having fibroids, possibly through the inhibition of aromatase [
         <a href="#rid13">
          13,49-51
         </a>
         ]. Other studies have not found this association [
         <a href="#rid36">
          36,48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5286904">
         <span class="h2">
          Genetics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies imply a familial predisposition to leiomyomas in some patients. There is also evidence of specific susceptibility genes for fibroids [
         <a href="#rid52">
          52-54
         </a>
         ].
        </p>
        <p>
         The genetics of fibroids is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5431.html" rel="external">
          "Uterine fibroids (leiomyomas): Histology and pathogenesis", section on 'Genetics'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5286678">
         <span class="h2">
          Other factors
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Race/ethnicity
         </strong>
         – The incidence rates of fibroids are typically found to be two- to threefold greater in Black females than in White females [
         <a href="#rid1">
          1,8,11,55,56
         </a>
         ]; differences in diet, lifestyle, psychosocial stress, perceived racism, and environmental exposures are thought to contribute to this disparity rather than race itself [
         <a href="#rid57">
          57-63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Black females compared with White females are also more likely to have clinically relevant fibroids (eg, larger uteri and fibroids, more severe anemia, faster growing fibroids) [
         <a href="#rid17">
          17,64-66
         </a>
         ], develop symptoms earlier (on average four to six years younger [
         <a href="#rid17">
          17,65
         </a>
         ]), and be managed surgically [
         <a href="#rid55">
          55,67-69
         </a>
         ]. The etiology of these differences are unknown and cannot be explained by known factors that vary by race [
         <a href="#rid8">
          8,70,71
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Data are mixed regarding whether Hispanic or Asian-Chinese females have an increased risk of uterine myomas compared with White females [
         <a href="#rid8">
          8,56,67,72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Stress/major life events
         </strong>
         – Chronic stress and major life events may be associated with an increased leiomyoma risk [
         <a href="#rid59">
          59,73
         </a>
         ]. In a meta-analysis including seven observational studies, there was a positive association with chronic psychological stress and fibroids, especially among non-Hispanic Black patients (odds ratio [OR] 1.24, 95% CI 1.14-1.34), and those with higher compared with lower categories of chronic stress (pooled OR 1.24, 95% CI 1.15-1.34) [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hypertension
         </strong>
         – Hypertension is associated with an increased leiomyoma risk. The risk is related to increased duration or severity of hypertension [
         <a href="#rid74">
          74,75
         </a>
         ], and may be linked through the angiotensin-converting enzyme pathway [
         <a href="#rid76">
          76,77
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diabetes
         </strong>
         – There are some studies showing a decreased leiomyoma risk among patients with type 2 diabetes, which appears to have a stronger association among European Americans than African Americans [
         <a href="#rid78">
          78-80
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Uterine infection
         </strong>
         – Uterine infection was previously associated with an increased risk of leiomyomas, but a subsequent study of self-reported reproductive tract infection did not find an association [
         <a href="#rid74">
          74,81
         </a>
         ], and one study found an inverse relationship with chlamydia exposure [
         <a href="#rid82">
          82
         </a>
         ]. Factors associated with cervical neoplasia are associated with a decreased risk [
         <a href="#rid74">
          74,83
         </a>
         ]. Additional study is indicated regarding infectious agents and fibroid risk.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H474411465">
         <span class="h1">
          PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the high prevalence, high recurrence risk following conservative treatment, and substantial impact on quality of life, preventive measures for uterine fibroids are needed. One study has suggested high physical activity, even after adjustment for body mass index and other confounders, was associated with a substantial decrease in risk of fibroid development [
         <a href="#rid84">
          84
         </a>
         ]. Etiologic investigations of vitamin D deficiency, inflammatory markers, hormonal receptors, and more are aimed at finding preventive targets.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Uterine leiomyomas are typically brought to medical attention due to symptoms or are found incidentally on pelvic imaging. Approximately 1 percent of females in a commercially insured population have fibroids that receive medical attention in a year [
         <a href="#rid85">
          85
         </a>
         ].
        </p>
        <p>
         The majority of myomas are small and asymptomatic, but many patients with fibroids have significant problems that interfere with some aspect of their lives and warrant therapy [
         <a href="#rid86">
          86
         </a>
         ]. These symptoms are related to the number, size, and location of the tumors. Myomas can occur as single or multiple tumors and range in size from microscopic to tens of centimeters. The size of the myomatous uterus is described in menstrual weeks as with the gravid uterus. As an example, a 20-week size myomatous uterus is not unusual and is often associated with heavy menses, increasing abdominal girth, and a sense of abdominal fullness similar to pregnancy.
        </p>
        <p>
         Symptoms are classified into three categories [
         <a href="#rid87">
          87
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Heavy or prolonged menstrual bleeding
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bulk-related symptoms, such as pelvic pressure and pain
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reproductive dysfunction (ie, infertility, miscarriage, obstetric complications)
        </p>
        <p>
        </p>
        <p>
         Among symptomatic patients with uterine fibroids, abnormal uterine bleeding (AUB) and menstrual cramps are the most common symptoms, occurring in approximately 26 to 29 percent of all patients. Black patients reported higher rates at 37 to 42 percent [
         <a href="#rid88">
          88
         </a>
         ]. Abdominal pain or tightness is reported in 19 percent of White patients and 34 percent of Black patients.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Heavy or prolonged menstrual bleeding
         </span>
         <span class="headingEndMark">
          —
         </span>
         Heavy and/or prolonged menses is the typical bleeding pattern with leiomyomas and the most common fibroid symptom [
         <a href="#rid89">
          89,90
         </a>
         ]. Intermenstrual bleeding and postmenopausal bleeding should prompt investigation to exclude endometrial pathology. For any AUB pattern, endometrial sampling should be performed if endometrial hyperplasia or carcinoma is suspected  (
         <a class="graphic graphic_table graphicRef58600" href="/z/d/graphic/58600.html" rel="external">
          table 1
         </a>
         ). It is important to keep in mind that a patient may have fibroids and concurrent endometrial neoplasia.
        </p>
        <p>
         Heavy uterine bleeding may be responsible for associated problems, such as iron deficiency anemia, social embarrassment, and lost productivity in the work force.
        </p>
        <p>
         The presence and degree of uterine bleeding are determined, in large part, by the location of the fibroid; size is of secondary importance  (
         <a class="graphic graphic_figure graphicRef53241" href="/z/d/graphic/53241.html" rel="external">
          figure 1
         </a>
         ) (see
         <a class="local">
          'Terminology and location'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Submucosal myomas that protrude into the uterine cavity (eg, types 0 and 1)  (
         <a class="graphic graphic_figure graphicRef59668" href="/z/d/graphic/59668.html" rel="external">
          figure 3
         </a>
         ) are most frequently related to significant heavy menstrual bleeding [
         <a href="#rid4">
          4,6,91
         </a>
         ]. As an example, a retrospective study that included 912 patients with leiomyomas found that those with submucosal myomas were significantly more likely to be anemic than patients with myomas in other locations (34 versus 25 percent) [
         <a href="#rid92">
          92
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intramural myomas are also commonly associated with heavy or prolonged menstrual bleeding, but subserosal fibroids are not considered a major risk for heavy menstrual bleeding.
        </p>
        <p>
        </p>
        <p>
         The mechanism(s) of profuse menses in patients with leiomyomas are unclear but may include both microscopic and macroscopic abnormalities of the uterine vasculature, impaired endometrial hemostasis, or molecular dysregulation of angiogenic factors [
         <a href="#rid93">
          93
         </a>
         ]. A study of endometrial histology showed distinct endometrial changes even remote from the location of fibroids, indicating that fibroids located intramurally could also contribute to bleeding [
         <a href="#rid94">
          94
         </a>
         ]. In addition, a study of uterine peristalsis demonstrates altered uterine contractility near submucosal fibroids; one theory is that this inhibits the usual ability of the uterus to contract during menses [
         <a href="#rid95">
          95
         </a>
         ].
        </p>
        <p>
         The evaluation of patients with AUB is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3263.html" rel="external">
          "Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H91444918">
         <span class="h2">
          Bulk-related symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         The myomatous uterus is enlarged and irregularly shaped and can cause specific symptoms due to pressure from myomas at particular locations. These symptoms and findings include pelvic pain or pressure, urinary tract or bowel obstruction, or venous compression.
        </p>
        <p class="headingAnchor" id="H3525968608">
         <span class="h3">
          Pelvic pressure or pain
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, pain is an underappreciated symptom of uterine fibroids. Pain may present as lower back pain, pelvic pain, and/or menstrual pain [
         <a href="#rid96">
          96
         </a>
         ]. Pelvic pressure, abdominal bloating, and abdominal protrusion may also be reported.
        </p>
        <p class="headingAnchor" id="H2608297740">
         <span class="h3">
          Urinary tract or bowel issues
         </span>
         <span class="headingEndMark">
          —
         </span>
         The urinary tract or bowel may be compressed by fibroids, depending on their size and location. Symptoms and findings include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urinary symptoms – A heterogeneous group of urinary symptoms including frequency, difficulty emptying the bladder, or, rarely, complete urinary obstruction may all occur in up to 60 percent of patients with fibroids [
         <a href="#rid86">
          86
         </a>
         ]. Bladder symptoms sometimes arise when an anterior fibroid presses directly on the bladder or a posterior fibroid pushes the entire uterus forward. In a small cohort study of patients with fibroids on ultrasound, 14 percent demonstrated hydronephrosis, more commonly on the right. Fibroids associated with hydronephrosis were larger with an average largest fibroid of 6 cm and a uterine size of 18 weeks [
         <a href="#rid97">
          97
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bowel symptoms – Fibroids that place pressure on the rectum can result in constipation.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H634451922">
         <span class="h3">
          Venous compression
         </span>
         <span class="headingEndMark">
          —
         </span>
         Very large uteri may compress the vena cava and lead to an increase in thromboembolic risk [
         <a href="#rid98">
          98-100
         </a>
         ]. One small study has reported thromboembolism as the presenting complaint in approximately 4 percent patients with an enlarged fibroid uterus [
         <a href="#rid98">
          98
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1317610711">
         <span class="h2">
          Other pain or discomfort issues
         </span>
        </p>
        <p class="headingAnchor" id="H453365123">
         <span class="h3">
          Painful menses
         </span>
         <span class="headingEndMark">
          —
         </span>
         Painful menses is reported by many patients with fibroids. This pain in many patients appears to be correlated with heavy menstrual flow and/or passage of clots.
        </p>
        <p class="headingAnchor" id="H745765887">
         <span class="h3">
          Painful intercourse
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is controversial whether patients with fibroids are more likely to experience painful intercourse than those without fibroids [
         <a href="#rid101">
          101,102
         </a>
         ]. However, among patients with fibroids, anterior or fundal fibroids are the most likely to be associated with deep pain with intercourse. Number and size of fibroids do not appear to influence the incidence or intensity of painful intercourse.
        </p>
        <p class="headingAnchor" id="H3784133710">
         <span class="h3">
          Fibroid degeneration or torsion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infrequently, fibroids cause acute pain from breaking down of the fibroid tissue (eg, carneous or red degeneration)  (
         <a class="graphic graphic_picture graphicRef60975" href="/z/d/graphic/60975.html" rel="external">
          picture 2
         </a>
         ) or torsion of a pedunculated tumor.
        </p>
        <p>
         Fibroid degeneration typically results in pelvic pain and may be associated with a low-grade fever, uterine tenderness on palpation, elevated white blood cell count, or peritoneal signs. The discomfort resulting from degenerating fibroids is self-limited, lasting from days to a few weeks, and usually responds to nonsteroidal anti-inflammatory drugs.
        </p>
        <p>
         Diagnosis of fibroid degeneration is based on the presence of a fibroid with a typical symptom pattern. On ultrasound, a potential diagnosis of degeneration is suggested when pain is present when scanning directly over the fibroid  (
         <a class="graphic graphic_diagnosticimage graphicRef64825" href="/z/d/graphic/64825.html" rel="external">
          image 2
         </a>
         ). In cases where the etiology of pain is unclear, pelvic magnetic resonance imaging with gadolinium can be useful to make the diagnosis of degeneration since regions of degeneration within fibroids do not have enhancement following contrast administration [
         <a href="#rid103">
          103
         </a>
         ]. If acute pain is the sole indication for surgery for uterine fibroids, other disease processes, such as endometriosis, renal colic, or rare diagnoses such as pelvic tuberculosis, should be carefully excluded [
         <a href="#rid104">
          104,105
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7384.html" rel="external">
          "Endometriosis in adults: Pathogenesis, epidemiology, and clinical impact"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4006690167">
         <span class="h2">
          Infertility or obstetric complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Leiomyomas that distort the uterine cavity (submucosal or intramural with an intracavitary component) have been thought to result in difficulty conceiving a pregnancy and an increased risk of miscarriage [
         <a href="#rid106">
          106
         </a>
         ]. However, a large prospective cohort study that identified fibroids in the first trimester of pregnancy found that, while fibroids were associated with miscarriage in univariate analysis, in multivariate analysis, increasing age appeared to be the primary driver of this relationship [
         <a href="#rid107">
          107
         </a>
         ]. Similar findings were obtained in a systematic review that addressed confounders [
         <a href="#rid108">
          108
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5478.html" rel="external">
          "Uterine fibroids (leiomyomas): Treatment overview", section on 'Impact of fibroids on fertility'
         </a>
         .)
        </p>
        <p>
         In addition, leiomyomas have been associated with adverse pregnancy outcomes (eg, placental abruption, fetal growth restriction, malpresentation, and preterm labor and birth). (See
         <a class="medical medical_review" href="/z/d/html/6801.html" rel="external">
          "Uterine fibroids (leiomyomas): Issues in pregnancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2727401524">
         <span class="h2">
          Other issues
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prolapsed fibroid
         </strong>
         – Infrequently, a submucosal leiomyoma will prolapse through the cervix and present with a mass, bleeding, and possible ulceration or infection. (See
         <a class="medical medical_review" href="/z/d/html/3295.html" rel="external">
          "Uterine fibroids (leiomyomas): Prolapsed fibroids"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Endocrine effects
         </strong>
         – Rare symptoms of fibroid tumors where fibroids can secrete ectopic hormones include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Polycythemia from autonomous production of erythropoietin [
         <a href="#rid109">
          109
         </a>
         ].
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypercalcemia from autonomous production of parathyroid hormone-related protein [
         <a href="#rid110">
          110
         </a>
         ].
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hyperprolactinemia [
         <a href="#rid111">
          111
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          DIAGNOSTIC EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical diagnosis of uterine leiomyomas is made based on a pelvic examination and pelvic ultrasound findings consistent with a uterine leiomyoma. Characteristic symptoms further support the clinical diagnosis, although many patients are asymptomatic. A definitive diagnosis by pathology evaluation is not obtained in all cases but should be pursued if there is reason to be suspicious that the uterine mass may not be a fibroid, but rather may be a uterine precancer or cancer. (See
         <a class="medical medical_review" href="/z/d/html/14203.html" rel="external">
          "Uterine fibroids (leiomyomas): Differentiating fibroids from uterine sarcomas"
         </a>
         .)
        </p>
        <p>
         The pelvic examination findings are typically of an enlarged, mobile uterus with an irregular contour on bimanual pelvic examination; however, small submucosal or intramural fibroids will not produce a noticeably enlarged uterus or an irregular contour. The most common symptoms are heavy or prolonged menstrual bleeding, and fibroids may be associated with pelvic pain, infertility, or other symptoms. Typically, the clinical diagnosis is confirmed with a pelvic ultrasound.
        </p>
        <p class="headingAnchor" id="H34078034">
         <span class="h2">
          History
         </span>
         <span class="headingEndMark">
          —
         </span>
         A medical history is taken, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptoms related to fibroids – The most common presenting symptoms of uterine fibroids are heavy or prolonged menstrual bleeding, pelvic pain or pressure, and infertility. For all symptoms, the duration, severity, and impact on quality of life should be assessed.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         It is important to assess the severity of heavy or prolonged menstrual bleeding. A menstrual history is taken and the volume and duration of bleeding elicited. Questions to assess uterine bleeding are shown in the table  (
         <a class="graphic graphic_table graphicRef69390" href="/z/d/graphic/69390.html" rel="external">
          table 2
         </a>
         ). For patients with heavy menstrual bleeding, questionnaires may help to assess the risk of a concomitant bleeding disorder [
         <a href="#rid112">
          112
         </a>
         ]. If there is any possibility the patient is pregnant, pregnancy testing should be performed. In addition, based on the bleeding pattern and risk factors, the clinician should consider the risk of endometrial hyperplasia or cancer and whether endometrial sampling should be performed  (
         <a class="graphic graphic_table graphicRef58600" href="/z/d/graphic/58600.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients with pelvic pain or pressure, the location, severity, and characteristics of the pain should be assessed. Pain related to fibroids is not likely to have an acute onset, except in the infrequent cases of fibroid torsion and degeneration. In addition, while some patients with fibroids experience painful menses, the pain associated with fibroids can also be noncyclic. Pain associated with menses may also indicate adenomyosis, endometriosis, or primary painful menses.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Patients should be asked about other potential pain or bulk-related symptoms, including dyspareunia, urinary retention, or constipation.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The patient should be asked about infertility, recurrent miscarriage, or obstetric complications that may be related to fibroids.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obstetric and gynecologic history, including prior history of uterine fibroids, history of pelvic pain, obstetric or gynecologic surgeries, and risk factors for uterine malignancies other than endometrial carcinoma (sarcoma, carcinosarcoma). Risk factors for sarcoma include postmenopausal status, Black race,
         <a class="drug drug_general" data-topicid="9972" href="/z/d/drug information/9972.html" rel="external">
          tamoxifen
         </a>
         , pelvic radiation, and hereditary leiomyomatosis and renal cell carcinoma. (See
         <a class="medical medical_review" href="/z/d/html/3203.html" rel="external">
          "Clinical features, diagnosis, staging, and treatment of uterine carcinosarcoma", section on 'Epidemiology and risk factors'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3211.html" rel="external">
          "Uterine sarcoma: Classification, epidemiology, clinical manifestations, and diagnosis", section on 'Risk factors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Relevant medical and surgical history, including those that are part of the differential diagnosis or may exacerbate the symptoms of a pelvic mass, pelvic pain, or abnormal uterine bleeding. This includes thyroid dysfunction, coagulation disorders, anticoagulant medications, nongynecologic conditions that cause pelvic or abdominal pain or mass, and prior pelvic or abdominal surgery.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5287492">
         <span class="h2">
          Physical examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         The physical examination includes an abdominal and pelvic examination. Vital signs are taken, as appropriate. Fibroids are rarely associated with fever, except in some patients with degenerating fibroids. Patients with severe heavy menstrual bleeding may become anemic, but in otherwise healthy reproductive-age patients, a significant change in heart rate or blood pressure is rare as part of the clinical presentation.
        </p>
        <p>
         The abdominal examination should include palpation for a pelvic-abdominal mass. Large fibroid uteri can be palpated abdominally. The level of the uterine fundus should be noted.
        </p>
        <p>
         A thorough pelvic examination is performed. On bimanual pelvic examination, the size, contour, and mobility should be noted. An enlarged, mobile uterus with an irregular contour is consistent with a leiomyomatous uterus. These findings are helpful to follow changes in the uterus over time and to aid surgical planning (eg, transverse or vertical incision, vaginal surgery or abdominal approach).
        </p>
        <p>
         The size is described in terms of the fundal height in the superior-inferior axis in comparison to a gravid uterus: Twelve weeks is palpable just above the pubic symphysis, 16 weeks is midway between the symphysis and umbilicus, and 20 weeks is at the umbilicus. An increase in size or an irregular contour may not be noted if the patient has small intramural or submucosal fibroids.
        </p>
        <p>
         An enlarged uterus that is fixed raises suspicion of an inflammatory process (eg, endometriosis) or malignancy.
        </p>
        <p>
         Infrequently, on speculum examination, a prolapsed submucosal fibroid is visible at the external cervical os. Prolapsed fibroids should be removed and are distinguished from a large endocervical or endometrial polyp by the firm consistency of the tissue and by pathology evaluation. (See
         <a class="medical medical_review" href="/z/d/html/3295.html" rel="external">
          "Uterine fibroids (leiomyomas): Prolapsed fibroids"
         </a>
         .)
        </p>
        <p>
         Cervical fibroids can present as an enlargement of the cervix seen during speculum examination or felt on bimanual examination. A pedunculated cervical fibroid can also appear like a prolapsing fibroid. Cervical fibroids generally have to be confirmed by an imaging study.
        </p>
        <p class="headingAnchor" id="H3671505219">
         <span class="h2">
          Laboratory testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Laboratory testing does not have a role in the diagnosis of uterine leiomyomas but is important in evaluating for other associated conditions, including:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pregnancy
         </strong>
         – A urine or serum human chorionic gonadotropin is ordered if the patient may be pregnant.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anemia
         </strong>
         – A hemoglobin/hematocrit should be ordered to diagnose anemia; a ferritin level may also be obtained. For those with anemia, clinicians must also consider concomitant etiologies, including bleeding disorders. This is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7133.html" rel="external">
          "Diagnostic approach to anemia in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1367.html" rel="external">
          "Approach to the adult with a suspected bleeding disorder"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Endometrial hyperplasia or carcinoma
         </strong>
         – Endometrial biopsy is performed for patients with abnormal uterine bleeding or risk factors for endometrial hyperplasia and/or carcinoma (eg, type 2 diabetes mellitus, obesity, chronic anovulation). (See
         <a class="medical medical_review" href="/z/d/html/3232.html" rel="external">
          "Overview of the evaluation of the endometrium for malignant or premalignant disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There is also some evidence that uterine sarcomas can be diagnosed by endometrial biopsy. (See
         <a class="medical medical_review" href="/z/d/html/14203.html" rel="external">
          "Uterine fibroids (leiomyomas): Differentiating fibroids from uterine sarcomas", section on 'Endometrial sampling'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5287506">
         <span class="h2">
          Imaging and endoscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pelvic ultrasound is the imaging study of choice for uterine leiomyomas, based on the ability to visualize genital tract structures and cost-effectiveness. Ultrasound is typically performed in all patients, and then other studies, such as saline-infused sonogram, hysteroscopy, or magnetic resonance imaging (MRI), are ordered depending on the clinical indications.
        </p>
        <p>
         Computed tomography has little clinical utility in delineating the position of fibroids relative to the endometrium or myometrium [
         <a href="#rid113">
          113
         </a>
         ]. Hysterosalpingograms can also sometimes show the distortion of the endometrial cavity but are best reserved for the patient needing assessment of fallopian tube patency for fertility.
        </p>
        <p class="headingAnchor" id="H5287537">
         <span class="h3">
          Step one: Pelvic ultrasound
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pelvic ultrasound is the first-line study used to evaluate for uterine fibroids. Transvaginal ultrasound has high sensitivity (95 to 100 percent) for detecting myomas in uteri less than 10 gestational weeks' size [
         <a href="#rid114">
          114
         </a>
         ]. Precise localization of fibroids is limited in larger uteri or when there are many tumors. Fibroids are seen on ultrasound usually as hypoechoic, well-circumscribed round masses, frequently with shadowing; cellular fibroids may appear to be more isoechoic, making differentiation from the normal myometrium difficult, or hyperechoic. Adenomyomas can mimic the appearance of cellular fibroids or multiple small fibroids. Sarcoma is also difficult to differentiate on imaging.
        </p>
        <p>
         On imaging, calcification in a fibroid generally implies that it has degenerated. These calcifications can be seen on plain film as "popcorn" calcifications in the pelvis. On ultrasound, the calcifications may appear as clumps or rim-like calcifications within a mass  (
         <a class="graphic graphic_diagnosticimage graphicRef96899" href="/z/d/graphic/96899.html" rel="external">
          image 3
         </a>
         ). At times, only the calcification is seen and not the soft tissue component. In general, if compared with a sonogram prenecrosis, the fibroid size will be smaller once it calcifies.
        </p>
        <p>
         If fibroids are thought to be causing urinary tract obstruction, then a renal ultrasound can be obtained to assess for hydronephrosis. (See
         <a class="medical medical_review" href="/z/d/html/7174.html" rel="external">
          "Clinical manifestations and diagnosis of urinary tract obstruction (UTO) and hydronephrosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4291908966">
         <span class="h3">
          Step two: Evaluate the uterine cavity in patients with suspected submucous fibroids or those desiring fertility
         </span>
        </p>
        <p class="headingAnchor" id="H1086348094">
         <span class="h4">
          Saline infusion sonography
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          Saline
         </a>
         infusion sonography (sonohysterography) is an imaging study in which pelvic ultrasound is performed while saline is infused into the uterine cavity. Use of this technique allows identification of submucosal lesions (some of which may not be seen on routine ultrasonography) and intramural myomas that protrude into the cavity and characterizes the extent of protrusion into the endometrial cavity  (
         <a class="graphic graphic_diagnosticimage graphicRef51266" href="/z/d/graphic/51266.html" rel="external">
          image 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/3252.html" rel="external">
          "Saline infusion sonohysterography"
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          Saline
         </a>
         infusion sonography is helpful when planning a hysteroscopic resection of a fibroid or evaluating the potential risks of fertility associated with a fibroid.
        </p>
        <p class="headingAnchor" id="H5287677">
         <span class="h4">
          Hysteroscopy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diagnostic hysteroscopy is useful for visualizing the endometrial cavity. Similar to
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         infusion sonography, this allows evaluation for submucosal or protruding myometrial fibroids and can characterize the extent of protrusion. This can be performed in the office or operating room.
        </p>
        <p>
         When the entire fibroid is visualized arising from a pedicle, or has a broad base, the lesion is hysteroscopically classified as intracavitary (type 0 fibroid). However, when the fibroid abuts the endometrium or protrudes into the myometrium, the depth of penetration cannot be ascertained hysteroscopically. Additionally, hysteroscopy less accurately predicts the size of the myoma compared with ultrasound and sonohysterography [
         <a href="#rid115">
          115
         </a>
         ].
        </p>
        <p>
         Hysteroscopy can help in the planning of a hysteroscopic resection of a submucosal fibroid if ultrasound has already confirmed size and proximity to the endometrium and rule out small polyps not seen on ultrasound.
        </p>
        <p class="headingAnchor" id="H990450151">
         <span class="h3">
          Step three: Additional imaging as necessary when complex intervention is planned or malignant disease is suspected
         </span>
        </p>
        <p class="headingAnchor" id="H5287572">
         <span class="h4">
          Magnetic resonance imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         MRI is the most effective modality for visualizing the size and location of all uterine myomas and can distinguish among leiomyomas, adenomyosis, and adenomyomas. Due to the expense of this modality, its use is best reserved for procedural planning for complicated procedures. For instance, for patients with type 3 through 6 uterine fibroids, an MRI can help the surgeon plan for laparoscopic myomectomy to know the expected depth into the myometrium  (
         <a class="graphic graphic_figure graphicRef91085" href="/z/d/graphic/91085.html" rel="external">
          figure 2
         </a>
         ). It may also be useful before uterine artery embolization since imaging patterns predict uterine artery embolization outcome. MRI can also help identify features concerning for leiomyosarcoma [
         <a href="#rid116">
          116,117
         </a>
         ]. This is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/14203.html" rel="external">
          "Uterine fibroids (leiomyomas): Differentiating fibroids from uterine sarcomas", section on 'Imaging'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3299.html" rel="external">
          "Uterine fibroids (leiomyomas): Treatment with uterine artery embolization"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H382296272">
         <span class="h4">
          Role of contrast-enhanced ultrasound
         </span>
         <span class="headingEndMark">
          —
         </span>
         Contrast-enhanced ultrasound (CEUS) has been studied as an alternative to MRI for evaluating fibroids characteristics; intravenously injected gas-filled microbubbles allow for visualization of the micro- and macrovasculature providing contrast-enhanced images of the uterus that is not otherwise visualized with ultrasound [
         <a href="#rid118">
          118,119
         </a>
         ]. While CEUS is commonly used for imaging of other organs (eg, liver, heart), its diagnostic performance for evaluation of fibroids is limited and MRI is probably superior to CEUS for evaluation of fibroids and distinguishing fibroids and leiomyosarcoma. Thus, this approach remains investigational and further studies are needed.
        </p>
        <p class="headingAnchor" id="H1736900957">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Uterine leiomyomas are a clinical diagnosis based on pelvic imaging. The diagnosis is typically made based on a pelvic ultrasound finding of leiomyomas, although other imaging modalities may be used. The indication for pelvic imaging typically includes symptoms of abnormal uterine bleeding (AUB), pelvic pain or pressure, or infertility; some patients have an enlarged uterus on pelvic examination.
        </p>
        <p>
         In general, pathology confirmation is not required to proceed with management, except in cases in which another lesion is suspected, such as a uterine sarcoma or leiomyoma variant. Unfortunately, it is difficult to differentiate benign leiomyomas from these conditions, and thus, some cases will be wrongly diagnosed as leiomyomas. (See
         <a class="medical medical_review" href="/z/d/html/14203.html" rel="external">
          "Uterine fibroids (leiomyomas): Differentiating fibroids from uterine sarcomas"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1394163470">
         <span class="h2">
          Additional characteristics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Information on volume and location of tumors within the uterus, based on pelvic imaging, aids in determining the clinical impact and treatment planning. This includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Are submucosal fibroids present? – These are the most likely to be associated with AUB or infertility, although these issues can occur with fibroids in other locations.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Are fibroids in one or more than one location? – Treatment planning must take into consideration all fibroid locations. As an example, management of a single submucosal fibroid may be different than if there is a submucosal fibroids and several intramural fibroids.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Is the volume or location of fibroids consistent with bulk-related symptoms? – Pelvic pain or pressure is likely to occur only if the uterus is sufficiently enlarged. In addition, urinary symptoms may occur if there is an anterior fibroid that abuts the bladder, or bowel symptoms may occur if there is a posterior or left fibroid that puts pressure on the rectum or sigmoid colon.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Is there hydronephrosis? – Hydronephrosis due to ureteral obstruction by a fibroid uterus must be alleviated to avoid renal failure.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5289858">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of uterine leiomyomas includes other conditions that cause uterine enlargement, abnormal uterine bleeding (AUB), pelvic pain, or infertility. It is important to note that leiomyomas are a common condition, and other coexisting conditions may be the etiology of the presenting symptoms.
        </p>
        <p>
         The differential diagnosis of an enlarged uterus includes both benign and malignant conditions:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pregnancy
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Myometrial lesions:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Benign leiomyoma.
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Adenomyosis (diffuse infiltration of the myometrium) or adenomyoma.
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Leiomyoma variant.
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Leiomyosarcoma.
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Metastatic disease – This is very rarely the cause of an enlarged uterus and typically from another reproductive tract primary; these lesions are likely to be myometrial but may invade the endometrium [
         <a href="#rid120">
          120,121
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Endometrial lesions:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Benign submucosal leiomyoma
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Endometrial polyp – These tend to be small and are unlikely to cause an enlarged uterus
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Endometrial carcinoma (may invade into the myometrium) or hyperplasia
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Carcinosarcoma – Considered an epithelial neoplasm
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Endometrial stromal sarcoma (mimics endometrium but invades the myometrium)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hematometra (blood within the uterine cavity, usually following an intrauterine procedure [eg, dilation and curettage])
        </p>
        <p>
        </p>
        <p>
         Pregnancy should be excluded in any patient of reproductive age who presents with an enlarged uterus, AUB, and/or pelvic pain. (See
         <a class="medical medical_review" href="/z/d/html/440.html" rel="external">
          "Clinical manifestations and diagnosis of early pregnancy", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
         Most commonly, when faced with an enlarged uterus, uterine leiomyomas must be differentiated from uterine adenomyosis. Patients with adenomyosis more often present with a diffusely enlarged uterus, painful menses, and AUB. On examination in a patient with adenomyosis, the uterus is typically smooth, globular, and boggy. The two conditions are usually differentiated by imaging since each has a characteristic appearance on ultrasound. (See
         <a class="medical medical_review" href="/z/d/html/5489.html" rel="external">
          "Uterine adenomyosis"
         </a>
         .)
        </p>
        <p>
         Patients may develop adenomyomas, which are benign glandular tumors within the myometrium. These can closely resemble leiomyomas on imaging. Adenomyosis and fibroids often occur in the same patient, making differentiation more difficult [
         <a href="#rid122">
          122,123
         </a>
         ]. Intraoperatively, adenomyomas are generally more difficult to excise than leiomyomas. Leiomyomas are typically separated from the adjacent myometrium by a pseudocapsule. With adenomyomas, there is typically no tissue plane between the adenomyoma and the myometrium.
        </p>
        <p>
         Benign or malignant uterine neoplasms must be differentiated from leiomyomas. The most common neoplastic condition that is part of the differential diagnosis is endometrial carcinoma. This is the most common site of gynecologic cancer in developed countries. Patients present with uterine bleeding and may have a uterine mass. However, the ultrasound findings in endometrial carcinoma are likely to be a thickened endometrium or, in the case of more advanced disease, a lesion invading from the endometrium to the myometrium. This is a distinctly different appearance than a fibroid, which may be seen to distort the endometrial cavity, but not actually invade from the endometrium to the myometrium. Endometrial sampling is the best method of diagnosis for endometrial carcinoma and should be performed if this is a potential diagnosis  (
         <a class="graphic graphic_table graphicRef58600" href="/z/d/graphic/58600.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/3203.html" rel="external">
          "Clinical features, diagnosis, staging, and treatment of uterine carcinosarcoma"
         </a>
         .)
        </p>
        <p>
         Leiomyomas are a common condition, and thus, it may be presumed that a patient has myomas rather than a rare smooth muscle neoplasm. This includes leiomyoma variants that manifest some facets of malignancy yet lack others. For example, they may metastasize but not be locally invasive and be histologically benign. Some of these variants show no facets of malignancy. These lesions appear to be exceedingly rare. (See
         <a class="medical medical_review" href="/z/d/html/15676.html" rel="external">
          "Uterine fibroids (leiomyomas): Variants and smooth muscle tumors of uncertain malignant potential"
         </a>
         .)
        </p>
        <p>
         Clinicians should also consider the possibility of a uterine sarcoma. Uterine sarcoma is rare (3 to 7 per 100,000 in the United States population) and has a poor prognosis [
         <a href="#rid124">
          124
         </a>
         ]. Both leiomyomas and uterine sarcoma present as focal masses in the uterine myometrium. There are several histologic types of uterine sarcoma. The main type of sarcoma that may resemble a leiomyoma is leiomyosarcoma, which presents as a myometrial mass, often with AUB. In contrast, endometrial stromal sarcoma presents as an endometrial mass. However, this could potentially have a similar appearance to a submucosal leiomyoma. Differentiating benign leiomyomas from uterine sarcomas is a clinical challenge and most sarcomas are not detected preoperatively. If there is a suspicion of a uterine sarcoma, operative techniques that disrupt the specimen (eg, myomectomy, morcellation) should be avoided. (See
         <a class="medical medical_review" href="/z/d/html/14203.html" rel="external">
          "Uterine fibroids (leiomyomas): Differentiating fibroids from uterine sarcomas"
         </a>
         .)
        </p>
        <p>
         Adenomatoid tumors are an uncommon type of mass of the female reproductive tract that can be seen in the myometrium or in the adnexa (the most common place is actually next to the fallopian tube) [
         <a href="#rid125">
          125
         </a>
         ]. They are mesothelial proliferations and are not histologically related to adenomyosis. They may grossly mimic leiomyomas.
        </p>
        <p>
         The differential diagnosis of AUB is aided by pelvic imaging and a clinical description of the bleeding. Heavy or prolonged menstrual bleeding are typically the AUB patterns that are associated with leiomyomas, although these symptoms are also consistent with many other etiologies. Other AUB patterns, such as intermenstrual bleeding, irregular bleeding, or postmenopausal bleeding, are likely due to other causes. In the absence of a mass on pelvic ultrasound, leiomyomas can be excluded and other etiologies should be investigated  (
         <a class="graphic graphic_table graphicRef90595" href="/z/d/graphic/90595.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_figure graphicRef90483" href="/z/d/graphic/90483.html" rel="external">
          figure 4
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/3263.html" rel="external">
          "Abnormal uterine bleeding in nonpregnant reproductive-age patients: Terminology, evaluation, and approach to diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5421.html" rel="external">
          "Approach to the patient with postmenopausal uterine bleeding"
         </a>
         .)
        </p>
        <p>
         Pelvic pain is a broad symptom category, and clarifying with the patient regarding the characteristics of the pain (ie, location, severity, timing of onset, duration, pattern, sensation, associated factors) is helpful in working through the differential diagnosis  (
         <a class="graphic graphic_table graphicRef112656" href="/z/d/graphic/112656.html" rel="external">
          table 4
         </a>
         ). Gastrointestinal, urinary tract, or other sources of pelvic pain should also be considered. In general, pain is not a major symptom in patients with fibroids. If discomfort is present, it is likely to be chronic, intermittent, dull pressure or pain. (See
         <a class="medical medical_review" href="/z/d/html/5490.html" rel="external">
          "Chronic pelvic pain in nonpregnant adult females: Causes"
         </a>
         .)
        </p>
        <p>
         Female infertility has many etiologies. Fibroids are usually discovered, if present, on pelvic ultrasound that is part of the routine evaluation.
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          NATURAL HISTORY
         </span>
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Premenopausal patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         With modern pelvic imaging, we have achieved an increased appreciation of the variability of growth and shrinkage of leiomyomas
         <strong>
         </strong>
         during the reproductive years [
         <a href="#rid66">
          66,126,127
         </a>
         ]. Prospective studies have found that between 7 to 40 percent of fibroids regress over six months to three years [
         <a href="#rid66">
          66,126
         </a>
         ]. There is also an increased appreciation of postpartum regression of fibroids [
         <a href="#rid26">
          26,128
         </a>
         ].
        </p>
        <p>
         Representative studies include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In one prospective study of 64 patients (mean age 44 years) with fibroids, the average growth rate was 1.2 cm in diameter over 2.5 years (range 0.9 to 6.8 cm) [
         <a href="#rid126">
          126
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A second study followed 72 patients with a total of 262 fibroids with magnetic resonance imaging (MRI) and reported a median growth rate of 9 percent at six-month follow-up. [
         <a href="#rid66">
          66
         </a>
         ]. There was wide variation in the growth of individual fibroids across all study participants (range decrease in size of 89 percent to increase in size of 138 percent) and for different fibroids within each patient. Within this prospective study, 36 patients with a total of 101 fibroids were evaluated with MRI at all time points for one year [
         <a href="#rid129">
          129
         </a>
         ]. Increase in volume of ≥30 percent in a three-month period was found in 37 myomas; rapid growth was more likely in tumors that were ≤5 cm in diameter.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1199430868">
         <span class="h3">
          Postpartum remodeling
         </span>
         <span class="headingEndMark">
          —
         </span>
         It has been hypothesized that the postpartum remodeling of the uterus may have the effect of clearing smaller fibroids [
         <a href="#rid130">
          130
         </a>
         ]. One study supported this hypothesis with the finding that over one-third of participants with a single fibroid identified during pregnancy had none on postpartum ultrasound, and almost 80 percent of fibroids were smaller following pregnancy [
         <a href="#rid128">
          128
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5291329">
         <span class="h2">
          Postmenopausal patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         At menopause, menstrual cyclicity stops and steroid hormone levels wane, and there is a cessation of the abnormal uterine bleeding symptoms associated with fibroids. Most, but not all, patients have shrinkage of leiomyomas at menopause.
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h3">
          Patients on hormone therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Use of menopausal hormone therapy may cause some patients with leiomyomas to continue to have symptoms after menopause. The risk of symptoms may depend, in part, on the location of the fibroid (higher if submucosal [
         <a href="#rid131">
          131
         </a>
         ]) and type of estrogen preparation (higher with transdermal estrogen in some studies [
         <a href="#rid132">
          132,133
         </a>
         ] but not others [
         <a href="#rid134">
          134
         </a>
         ]).
        </p>
        <p>
         A systematic review including five randomized controlled trials found that postmenopausal hormone therapy was associated with some myoma growth, but this typically occurred without clinical symptoms [
         <a href="#rid135">
          135
         </a>
         ]. These findings were confirmed in a subsequent prospective study [
         <a href="#rid136">
          136
         </a>
         ]. Thus, the presence of leiomyomas is not a contraindication to use of postmenopausal hormone therapy and postmenopausal hormone therapy does not lead to development of new symptomatic fibroids in most patients. (See
         <a class="medical medical_review" href="/z/d/html/7427.html" rel="external">
          "Menopausal hormone therapy: Benefits and risks", section on 'Other possible risks'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1425157642">
         <span class="h1">
          IMPACT ON PATIENT AND SOCIETY
         </span>
        </p>
        <p class="headingAnchor" id="H3279351957">
         <span class="h2">
          Quality of life
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with symptomatic fibroids report multiple symptoms as well as concerns about fibroids affecting relationships, employment, and overall health. In a systematic review of 18 randomized trials and 39 observational studies, patients with fibroids reported psychosocial stressors related to bodily pain, mental health, and social functioning, and had quality-of-life scores that were similar to, or lower (more severe) than, patients with other chronic diseases (eg, diabetes mellitus, breast cancer, cardiovascular disease) [
         <a href="#rid137">
          137
         </a>
         ].
        </p>
        <p>
         Compared with White patients, Black patients experience more severe disease based on their symptoms and have more extensive disease at the time of hysterectomy [
         <a href="#rid17">
          17,65
         </a>
         ]. There is growing evidence of increases in symptomatology for Black patients with fibroids apart from those seeking surgical therapy, increased impairment of quality of life, different concerns regarding fibroids and the consequences of fibroid therapies, and less satisfaction with the information they receive about fibroids [
         <a href="#rid86">
          86
         </a>
         ]. Importantly, Black patients were almost three times as likely to be concerned about fertility and healthy pregnancy [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3264483890">
         <span class="h2">
          Economic impact
         </span>
         <span class="headingEndMark">
          —
         </span>
         Uterine fibroids are costly to the health care system and the individual patient. Because they are the cause of 40 percent of hysterectomies, surgical costs and missed work days during recovery can add great expense to the treatment. Fibroids account for approximately USD $34 billion United States health care dollars annually [
         <a href="#rid138">
          138
         </a>
         ]. Annual excess cost per patient with fibroids was estimated at more than USD $4600, which included USD $771 in missed work days [
         <a href="#rid139">
          139
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3979706480">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111091.html" rel="external">
          "Society guideline links: Uterine fibroids (leiomyomas)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15364467">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15421.html" rel="external">
          "Patient education: Uterine fibroids (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/8408.html" rel="external">
          "Patient education: Uterine fibroids (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5291363">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Terminology
         </strong>
         – Uterine leiomyomas (fibroids or myomas) are benign monoclonal tumors arising from the smooth muscle cells of the myometrium. Fibroids are typically described according to their location in the uterus (submucosal, intramural, subserosal, cervical)  (
         <a class="graphic graphic_figure graphicRef53241" href="/z/d/graphic/53241.html" rel="external">
          figure 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef91085" href="/z/d/graphic/91085.html" rel="external">
          figure 2
         </a>
         ). (See
         <a class="local">
          'Terminology and location'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevalence
         </strong>
         – Uterine leiomyomas are the most common pelvic tumor in females. The incidence of leiomyomas parallels the life cycle changes of the reproductive hormones estrogen and progesterone. (See
         <a class="local">
          'Prevalence'
         </a>
         above and
         <a class="local">
          'Reproductive and endocrine factors'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – Symptoms attributable to uterine leiomyomas can generally be classified into three distinct categories: abnormal uterine bleeding (AUB), pelvic pressure and pain, and reproductive dysfunction. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – Uterine leiomyomas are a clinical diagnosis typically made based on a pelvic ultrasound finding of leiomyomas, although other imaging modalities may be used. The indication for pelvic imaging typically includes symptoms of AUB, pelvic pain or pressure, or infertility; some patients have an enlarged uterus on pelvic examination.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In general, pathology confirmation is
         <strong>
          not
         </strong>
         required to proceed with management, except in cases in which another more serious lesion is suspected, such as a uterine sarcoma or leiomyoma variant. Unfortunately, it is difficult to differentiate benign leiomyomas from these conditions, and thus, some cases will be wrongly diagnosed as leiomyomas. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Imaging
         </strong>
         – Transvaginal ultrasound is the most widely used imaging modality for evaluating fibroids due to its availability and cost-effectiveness.
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          Saline
         </a>
         infusion sonography (sonohysterography) improves characterization of the extent of protrusion into the endometrial cavity by submucous myomas and allows identification of some intracavitary lesions not seen on routine ultrasonography. (See
         <a class="local">
          'Imaging and endoscopy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Postmenopausal patients
         </strong>
         – Relief of symptoms related to fibroids usually occurs at the time of menopause, when menstrual cyclicity stops and steroid hormone levels wane. Most, but not all, patients have shrinkage of leiomyomas at menopause. (See
         <a class="local">
          'Postmenopausal patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role of hormone therapy
         </strong>
         – Use of postmenopausal hormone therapy may cause some patients with leiomyomas to continue to have symptoms after menopause. Hormone therapy may be associated with an increase in size of existing myomas but not with the development of new myomas. (See
         <a class="local">
          'Patients on hormone therapy'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Baird DD, Dunson DB, Hill MC, et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003; 188:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serden SP, Brooks PG. Treatment of abnormal uterine bleeding with the gynecologic resectoscope. J Reprod Med 1991; 36:697.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munro MG, Critchley HO, Fraser IS, FIGO Menstrual Disorders Working Group. The FIGO classification of causes of abnormal uterine bleeding in the reproductive years. Fertil Steril 2011; 95:2204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wamsteker K, Emanuel MH, de Kruif JH. Transcervical hysteroscopic resection of submucous fibroids for abnormal uterine bleeding: results regarding the degree of intramural extension. Obstet Gynecol 1993; 82:736.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laughlin-Tommaso SK, Hesley GK, Hopkins MR, et al. Clinical limitations of the International Federation of Gynecology and Obstetrics (FIGO) classification of uterine fibroids. Int J Gynaecol Obstet 2017; 139:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buttram VC Jr, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 1981; 36:433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. BJOG 2017; 124:1501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marshall LM, Spiegelman D, Barbieri RL, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol 1997; 90:967.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Downes E, Sikirica V, Gilabert-Estelles J, et al. The burden of uterine fibroids in five European countries. Eur J Obstet Gynecol Reprod Biol 2010; 152:96.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol 1990; 94:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marsh EE, Ekpo GE, Cardozo ER, et al. Racial differences in fibroid prevalence and ultrasound findings in asymptomatic young women (18-30 years old): a pilot study. Fertil Steril 2013; 99:1951.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wegienka G, Havstad S, Coleman C, et al. Ultrasound-Confirmed, Age-Specific Uterine Leiomyoma Incidence in a Cohort of Black Individuals. Obstet Gynecol 2022; 140:1042.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross RK, Pike MC, Vessey MP, et al. Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J (Clin Res Ed) 1986; 293:359.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parazzini F, La Vecchia C, Negri E, et al. Epidemiologic characteristics of women with uterine fibroids: a case-control study. Obstet Gynecol 1988; 72:853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marshall LM, Spiegelman D, Goldman MB, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril 1998; 70:432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wise LA, Palmer JR, Harlow BL, et al. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: a prospective study. Am J Epidemiol 2004; 159:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huyck KL, Panhuysen CI, Cuenco KT, et al. The impact of race as a risk factor for symptom severity and age at diagnosis of uterine leiomyomata among affected sisters. Am J Obstet Gynecol 2008; 198:168.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hodge JC, T Cuenco K, Huyck KL, et al. Uterine leiomyomata and decreased height: a common HMGA2 predisposition allele. Hum Genet 2009; 125:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dragomir AD, Schroeder JC, Connolly A, et al. Potential risk factors associated with subtypes of uterine leiomyomata. Reprod Sci 2010; 17:1029.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adams Hillard PJ. Menstruation in adolescents: what's normal, what's not. Ann N Y Acad Sci 2008; 1135:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiaffarino F, Parazzini F, La Vecchia C, et al. Use of oral contraceptives and uterine fibroids: results from a case-control study. Br J Obstet Gynaecol 1999; 106:857.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parazzini F, Negri E, La Vecchia C, et al. Oral contraceptive use and risk of uterine fibroids. Obstet Gynecol 1992; 79:430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lumbiganon P, Rugpao S, Phandhu-fung S, et al. Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicentre case--control study. Br J Obstet Gynaecol 1996; 103:909.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venkatachalam S, Bagratee JS, Moodley J. Medical management of uterine fibroids with medroxyprogesterone acetate (Depo Provera): a pilot study. J Obstet Gynaecol 2004; 24:798.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harmon QE, Patchel SA, Zhao S, et al. Depot Medroxyprogesterone Acetate Use and the Development and Progression of Uterine Leiomyoma. Obstet Gynecol 2022; 139:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laughlin SK, Hartmann KE, Baird DD. Postpartum factors and natural fibroid regression. Am J Obstet Gynecol 2011; 204:496.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gunes M, Ozdegirmenci O, Kayikcioglu F, et al. The effect of levonorgestrel intrauterine system on uterine myomas: a 1-year follow-up study. J Minim Invasive Gynecol 2008; 15:735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grigorieva V, Chen-Mok M, Tarasova M, Mikhailov A. Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas. Fertil Steril 2003; 79:1194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baird DD, Newbold R. Prenatal diethylstilbestrol (DES) exposure is associated with uterine leiomyoma development. Reprod Toxicol 2005; 20:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frankel T, Benjamin F. Rapid enlargement of a uterine fibroid after clomiphene therapy. J Obstet Gynaecol Br Commonw 1973; 80:764.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Felmingham JE, Corcoran R. Letter: Rapid enlargement of a uterine fibroid after clomiphene therapy. Br J Obstet Gynaecol 1975; 82:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klip H, van Leeuwen FE, Schats R, et al. Risk of benign gynaecological diseases and hormonal disorders according to responsiveness to ovarian stimulation in IVF: a follow-up study of 8714 women. Hum Reprod 2003; 18:1951.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           James-Todd TM, Chiu YH, Zota AR. Racial/ethnic disparities in environmental endocrine disrupting chemicals and women's reproductive health outcomes: epidemiological examples across the life course. Curr Epidemiol Rep 2016; 3:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sato F, Nishi M, Kudo R, Miyake H. Body fat distribution and uterine leiomyomas. J Epidemiol 1998; 8:176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wise LA, Palmer JR, Spiegelman D, et al. Influence of body size and body fat distribution on risk of uterine leiomyomata in U.S. black women. Epidemiology 2005; 16:346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marshall LM, Spiegelman D, Manson JE, et al. Risk of uterine leiomyomata among premenopausal women in relation to body size and cigarette smoking. Epidemiology 1998; 9:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faerstein E, Szklo M, Rosenshein N. Risk factors for uterine leiomyoma: a practice-based case-control study. I. African-American heritage, reproductive history, body size, and smoking. Am J Epidemiol 2001; 153:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terry KL, De Vivo I, Hankinson SE, et al. Anthropometric characteristics and risk of uterine leiomyoma. Epidemiology 2007; 18:758.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiaffarino F, Parazzini F, La Vecchia C, et al. Diet and uterine myomas. Obstet Gynecol 1999; 94:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wise LA, Radin RG, Palmer JR, et al. Intake of fruit, vegetables, and carotenoids in relation to risk of uterine leiomyomata. Am J Clin Nutr 2011; 94:1620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wise LA, Radin RG, Palmer JR, et al. A prospective study of dairy intake and risk of uterine leiomyomata. Am J Epidemiol 2010; 171:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Radin RG, Palmer JR, Rosenberg L, et al. Dietary glycemic index and load in relation to risk of uterine leiomyomata in the Black Women's Health Study. Am J Clin Nutr 2010; 91:1281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brasky TM, Bethea TN, Wesselink AK, et al. Dietary Fat Intake and Risk of Uterine Leiomyomata: A Prospective Ultrasound Study. Am J Epidemiol 2020; 189:1538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wise LA, Radin RG, Kumanyika SK, et al. Prospective study of dietary fat and risk of uterine leiomyomata. Am J Clin Nutr 2014; 99:1105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Terry KL, Missmer SA, Hankinson SE, et al. Lycopene and other carotenoid intake in relation to risk of uterine leiomyomata. Am J Obstet Gynecol 2008; 198:37.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baird DD, Hill MC, Schectman JM, Hollis BW. Vitamin d and the risk of uterine fibroids. Epidemiology 2013; 24:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halder SK, Sharan C, Al-Hendy A. 1,25-dihydroxyvitamin D3 treatment shrinks uterine leiomyoma tumors in the Eker rat model. Biol Reprod 2012; 86:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wise LA, Palmer JR, Harlow BL, et al. Risk of uterine leiomyomata in relation to tobacco, alcohol and caffeine consumption in the Black Women's Health Study. Hum Reprod 2004; 19:1746.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parazzini F, Negri E, La Vecchia C, et al. Uterine myomas and smoking. Results from an Italian study. J Reprod Med 1996; 41:316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barbieri RL, McShane PM, Ryan KJ. Constituents of cigarette smoke inhibit human granulosa cell aromatase. Fertil Steril 1986; 46:232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wesselink AK, Wegienka G, Coleman CM, et al. A prospective ultrasound study of cigarette smoking and uterine leiomyomata incidence and growth. Am J Obstet Gynecol 2023; 229:151.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eggert SL, Huyck KL, Somasundaram P, et al. Genome-wide linkage and association analyses implicate FASN in predisposition to Uterine Leiomyomata. Am J Hum Genet 2012; 91:621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mehine M, Kaasinen E, Mäkinen N, et al. Characterization of uterine leiomyomas by whole-genome sequencing. N Engl J Med 2013; 369:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mäkinen N, Vahteristo P, Bützow R, et al. Exomic landscape of MED12 mutation-negative and -positive uterine leiomyomas. Int J Cancer 2014; 134:1008.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Templeman C, Marshall SF, Clarke CA, et al. Risk factors for surgically removed fibroids in a large cohort of teachers. Fertil Steril 2009; 92:1436.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang D, Magaoay B, Rosen MP, Cedars MI. Presence of Fibroids on Transvaginal Ultrasonography in a Community-Based, Diverse Cohort of 996 Reproductive-Age Female Participants. JAMA Netw Open 2023; 6:e2312701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boynton-Jarrett R, Rich-Edwards JW, Jun HJ, et al. Abuse in childhood and risk of uterine leiomyoma: the role of emotional support in biologic resilience. Epidemiology 2011; 22:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wise LA, Laughlin-Tommaso SK. Epidemiology of Uterine Fibroids: From Menarche to Menopause. Clin Obstet Gynecol 2016; 59:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vines AI, Ta M, Esserman DA. The association between self-reported major life events and the presence of uterine fibroids. Womens Health Issues 2010; 20:294.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baird D, Wise LA. Childhood abuse and fibroids. Epidemiology 2011; 22:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wise LA, Palmer JR, Rosenberg L. Lifetime abuse victimization and risk of uterine leiomyomata in black women. Am J Obstet Gynecol 2013; 208:272.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wise LA, Palmer JR, Cozier YC, et al. Perceived racial discrimination and risk of uterine leiomyomata. Epidemiology 2007; 18:747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harmon QE, Actkins KV, Baird DD. Fibroid Prevalence-Still So Much to Learn. JAMA Netw Open 2023; 6:e2312682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Butt JL, Jeffery ST, Van der Spuy ZM. An audit of indications and complications associated with elective hysterectomy at a public service hospital in South Africa. Int J Gynaecol Obstet 2012; 116:112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kjerulff KH, Langenberg P, Seidman JD, et al. Uterine leiomyomas. Racial differences in severity, symptoms and age at diagnosis. J Reprod Med 1996; 41:483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peddada SD, Laughlin SK, Miner K, et al. Growth of uterine leiomyomata among premenopausal black and white women. Proc Natl Acad Sci U S A 2008; 105:19887.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilcox LS, Koonin LM, Pokras R, et al. Hysterectomy in the United States, 1988-1990. Obstet Gynecol 1994; 83:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore AB, Flake GP, Swartz CD, et al. Association of race, age and body mass index with gross pathology of uterine fibroids. J Reprod Med 2008; 53:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wechter ME, Stewart EA, Myers ER, et al. Leiomyoma-related hospitalization and surgery: prevalence and predicted growth based on population trends. Am J Obstet Gynecol 2011; 205:492.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laughlin SK, Schroeder JC, Baird DD. New directions in the epidemiology of uterine fibroids. Semin Reprod Med 2010; 28:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borah BJ, Laughlin-Tommaso SK, Myers ER, et al. Association Between Patient Characteristics and Treatment Procedure Among Patients With Uterine Leiomyomas. Obstet Gynecol 2016; 127:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laughlin SK, Baird DD, Savitz DA, et al. Prevalence of uterine leiomyomas in the first trimester of pregnancy: an ultrasound-screening study. Obstet Gynecol 2009; 113:630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Qin H, Lin Z, Vásquez E, Xu L. The association between chronic psychological stress and uterine fibroids risk: A meta-analysis of observational studies. Stress Health 2019; 35:585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faerstein E, Szklo M, Rosenshein NB. Risk factors for uterine leiomyoma: a practice-based case-control study. II. Atherogenic risk factors and potential sources of uterine irritation. Am J Epidemiol 2001; 153:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitro SD, Waetjen LE, Lee C, et al. Hypertension, cardiovascular risk factors, and uterine fibroid diagnosis in midlife: Study of women’s health across the nation (SWAN). Fertil Steril 2023; 120:e78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fischer NM, Nieuwenhuis TO, Singh B, et al. Angiotensin-Converting Enzyme Inhibitors Reduce Uterine Fibroid Incidence in Hypertensive Women. J Clin Endocrinol Metab 2021; 106:e650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stewart EA, Borah BJ. Uterine Fibroids and Hypertension: Steps Toward Understanding the Link. J Clin Endocrinol Metab 2021; 106:e1039.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Velez Edwards DR, Hartmann KE, Wellons M, et al. Evaluating the role of race and medication in protection of uterine fibroids by type 2 diabetes exposure. BMC Womens Health 2017; 17:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baird DD, Travlos G, Wilson R, et al. Uterine leiomyomata in relation to insulin-like growth factor-I, insulin, and diabetes. Epidemiology 2009; 20:604.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wise LA, Palmer JR, Stewart EA, Rosenberg L. Polycystic ovary syndrome and risk of uterine leiomyomata. Fertil Steril 2007; 87:1108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore KR, Cole SR, Dittmer DP, et al. Self-Reported Reproductive Tract Infections and Ultrasound Diagnosed Uterine Fibroids in African-American Women. J Womens Health (Larchmt) 2015; 24:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore KR, Smith JS, Cole SR, et al. Chlamydia trachomatis Seroprevalence and Ultrasound-Diagnosed Uterine Fibroids in a Large Population of Young African-American Women. Am J Epidemiol 2018; 187:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore KR, Smith JS, Laughlin-Tommaso SK, Baird DD. Cervical neoplasia-related factors and decreased prevalence of uterine fibroids among a cohort of African American women. Fertil Steril 2014; 101:208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baird DD, Dunson DB, Hill MC, et al. Association of physical activity with development of uterine leiomyoma. Am J Epidemiol 2007; 165:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee DW, Gibson TB, Carls GS, et al. Uterine fibroid treatment patterns in a population of insured women. Fertil Steril 2009; 91:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borah BJ, Nicholson WK, Bradley L, Stewart EA. The impact of uterine leiomyomas: a national survey of affected women. Am J Obstet Gynecol 2013; 209:319.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stewart EA. Clinical practice. Uterine fibroids. N Engl J Med 2015; 372:1646.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stewart EA, Nicholson WK, Bradley L, Borah BJ. The burden of uterine fibroids for African-American women: results of a national survey. J Womens Health (Larchmt) 2013; 22:807.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fraser IS, Critchley HO, Munro MG, et al. A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding. Fertil Steril 2007; 87:466.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Committee on Practice Bulletins—Gynecology. Practice bulletin no. 128: Diagnosis of abnormal uterine bleeding in reproductive-aged women. Obstet Gynecol 2012; 120:197. Reaffirmed 2021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wegienka G, Baird DD, Hertz-Picciotto I, et al. Self-reported heavy bleeding associated with uterine leiomyomata. Obstet Gynecol 2003; 101:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puri K, Famuyide AO, Erwin PJ, et al. Submucosal fibroids and the relation to heavy menstrual bleeding and anemia. Am J Obstet Gynecol 2014; 210:38.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stewart EA, Nowak RA. Leiomyoma-related bleeding: a classic hypothesis updated for the molecular era. Hum Reprod Update 1996; 2:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deligdish L, Loewenthal M. Endometrial changes associated with myomata of the uterus. J Clin Pathol 1970; 23:676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nishino M, Togashi K, Nakai A, et al. Uterine contractions evaluated on cine MR imaging in patients with uterine leiomyomas. Eur J Radiol 2005; 53:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Soliman AM, Margolis MK, Castelli-Haley J, et al. Impact of uterine fibroid symptoms on health-related quality of life of US women: evidence from a cross-sectional survey. Curr Med Res Opin 2017; 33:1971.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fletcher HM, Wharfe G, Williams NP, et al. Renal impairment as a complication of uterine fibroids: a retrospective hospital-based study. J Obstet Gynaecol 2013; 33:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fletcher H, Wharfe G, Williams NP, et al. Venous thromboembolism as a complication of uterine fibroids: a retrospective descriptive study. J Obstet Gynaecol 2009; 29:732.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shiota M, Kotani Y, Umemoto M, et al. Deep-vein thrombosis is associated with large uterine fibroids. Tohoku J Exp Med 2011; 224:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenfeld H, Byard RW. Lower extremity deep venous thrombosis with fatal pulmonary thromboembolism caused by benign pelvic space-occupying lesions--an overview. J Forensic Sci 2012; 57:665.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lippman SA, Warner M, Samuels S, et al. Uterine fibroids and gynecologic pain symptoms in a population-based study. Fertil Steril 2003; 80:1488.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrero S, Abbamonte LH, Giordano M, et al. Uterine myomas, dyspareunia, and sexual function. Fertil Steril 2006; 86:1504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laughlin SK, Stewart EA. Uterine leiomyomas: individualizing the approach to a heterogeneous condition. Obstet Gynecol 2011; 117:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mollica G, Pittini L, Minganti E, et al. Elective uterine myomectomy in pregnant women. Clin Exp Obstet Gynecol 1996; 23:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moore AR, Rogers FM, Dietrick D, Smith S. Extrapulmonary tuberculosis in pregnancy masquerading as a degenerating leiomyoma. Obstet Gynecol 2008; 111:550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pritts EA, Parker WH, Olive DL. Fibroids and infertility: an updated systematic review of the evidence. Fertil Steril 2009; 91:1215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hartmann KE, Velez Edwards DR, Savitz DA, et al. Prospective Cohort Study of Uterine Fibroids and Miscarriage Risk. Am J Epidemiol 2017; 186:1140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sundermann AC, Velez Edwards DR, Bray MJ, et al. Leiomyomas in Pregnancy and Spontaneous Abortion: A Systematic Review and Meta-analysis. Obstet Gynecol 2017; 130:1065.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoshida M, Koshiyama M, Fujii H, Konishi M. Erythrocytosis and a fibroid. Lancet 1999; 354:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ravakhah K, Gover A, Mukunda BN. Humoral hypercalcemia associated with a uterine fibroid. Ann Intern Med 1999; 130:702.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cordiano V. Complete remission of hyperprolactinemia and erythrocytosis after hysterectomy for a uterine fibroid in a woman with a previous diagnosis of prolactin-secreting pituitary microadenoma. Ann Hematol 2005; 84:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munro MG, Lukes AS, Abnormal Uterine Bleeding and Underlying Hemostatic Disorders Consensus Group. Abnormal uterine bleeding and underlying hemostatic disorders: report of a consensus process. Fertil Steril 2005; 84:1335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradley LD, Falcone T, Magen AB. Radiographic imaging techniques for the diagnosis of abnormal uterine bleeding. Obstet Gynecol Clin North Am 2000; 27:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dueholm M, Lundorf E, Hansen ES, et al. Accuracy of magnetic resonance imaging and transvaginal ultrasonography in the diagnosis, mapping, and measurement of uterine myomas. Am J Obstet Gynecol 2002; 186:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cicinelli E, Romano F, Anastasio PS, et al. Transabdominal sonohysterography, transvaginal sonography, and hysteroscopy in the evaluation of submucous myomas. Obstet Gynecol 1995; 85:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Omary RA, Vasireddy S, Chrisman HB, et al. The effect of pelvic MR imaging on the diagnosis and treatment of women with presumed symptomatic uterine fibroids. J Vasc Interv Radiol 2002; 13:1149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vedantham S, Sterling KM, Goodwin SC, et al. I. Uterine fibroid embolization: preprocedure assessment. Tech Vasc Interv Radiol 2002; 5:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stoelinga B, Juffermans L, Dooper A, et al. Contrast-Enhanced Ultrasound Imaging of Uterine Disorders: A Systematic Review. Ultrason Imaging 2021; 43:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torkzaban M, Machado P, Gupta I, et al. Contrast-Enhanced Ultrasound for Monitoring Non-surgical Treatments of Uterine Fibroids: A Systematic Review. Ultrasound Med Biol 2021; 47:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piura B, Yanai-Inbar I, Rabinovich A, et al. Abnormal uterine bleeding as a presenting sign of metastases to the uterine corpus, cervix and vagina in a breast cancer patient on tamoxifen therapy. Eur J Obstet Gynecol Reprod Biol 1999; 83:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reyes C, Murali R, Park KJ. Secondary Involvement of the Adnexa and Uterine Corpus by Carcinomas of the Uterine Cervix: A Detailed Morphologic Description. Int J Gynecol Pathol 2015; 34:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taran FA, Weaver AL, Coddington CC, Stewart EA. Understanding adenomyosis: a case control study. Fertil Steril 2010; 94:1223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brucker SY, Huebner M, Wallwiener M, et al. Clinical characteristics indicating adenomyosis coexisting with leiomyomas: a retrospective, questionnaire-based study. Fertil Steril 2014; 101:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecol Oncol 2004; 93:204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sangoi AR, McKenney JK, Schwartz EJ, et al. Adenomatoid tumors of the female and male genital tracts: a clinicopathological and immunohistochemical study of 44 cases. Mod Pathol 2009; 22:1228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeWaay DJ, Syrop CH, Nygaard IE, et al. Natural history of uterine polyps and leiomyomata. Obstet Gynecol 2002; 100:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawamura N, Ito F, Ichimura T, et al. Transient rapid growth of uterine leiomyoma in a postmenopausal woman. Oncol Rep 1999; 6:1289.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laughlin SK, Herring AH, Savitz DA, et al. Pregnancy-related fibroid reduction. Fertil Steril 2010; 94:2421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baird DD, Garrett TA, Laughlin SK, et al. Short-term change in growth of uterine leiomyoma: tumor growth spurts. Fertil Steril 2011; 95:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baird DD, Dunson DB. Why is parity protective for uterine fibroids? Epidemiology 2003; 14:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akkad AA, Habiba MA, Ismail N, et al. Abnormal uterine bleeding on hormone replacement: the importance of intrauterine structural abnormalities. Obstet Gynecol 1995; 86:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sener AB, Seçkin NC, Ozmen S, et al. The effects of hormone replacement therapy on uterine fibroids in postmenopausal women. Fertil Steril 1996; 65:354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polatti F, Viazzo F, Colleoni R, Nappi RE. Uterine myoma in postmenopause: a comparison between two therapeutic schedules of HRT. Maturitas 2000; 37:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palomba S, Sena T, Noia R, et al. Transdermal hormone replacement therapy in postmenopausal women with uterine leiomyomas. Obstet Gynecol 2001; 98:1053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ang WC, Farrell E, Vollenhoven B. Effect of hormone replacement therapies and selective estrogen receptor modulators in postmenopausal women with uterine leiomyomas: a literature review. Climacteric 2001; 4:284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang CH, Lee JN, Hsu SC, et al. Effect of hormone replacement therapy on uterine fibroids in postmenopausal women--a 3-year study. Maturitas 2002; 43:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Go VAA, Thomas MC, Singh B, et al. A systematic review of the psychosocial impact of fibroids before and after treatment. Am J Obstet Gynecol 2020; 223:674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cardozo ER, Clark AD, Banks NK, et al. The estimated annual cost of uterine leiomyomata in the United States. Am J Obstet Gynecol 2012; 206:211.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hartmann KE, Birnbaum H, Ben-Hamadi R, et al. Annual costs associated with diagnosis of uterine leiomyomata. Obstet Gynecol 2006; 108:930.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5486 Version 51.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12548202" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1835500" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Treatment of abnormal uterine bleeding with the gynecologic resectoscope.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21496802" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The FIGO classification of causes of abnormal uterine bleeding in the reproductive years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8414318" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Transcervical hysteroscopic resection of submucous fibroids for abnormal uterine bleeding: results regarding the degree of intramural extension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28715088" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Clinical limitations of the International Federation of Gynecology and Obstetrics (FIGO) classification of uterine fibroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7026295" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Uterine leiomyomata: etiology, symptomatology, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28296146" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Epidemiology of uterine fibroids: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9397113" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Variation in the incidence of uterine leiomyoma among premenopausal women by age and race.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20598796" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : The burden of uterine fibroids in five European countries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2220671" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The frequency of uterine leiomyomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23498888" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Racial differences in fibroid prevalence and ultrasound findings in asymptomatic young women (18-30 years old): a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36357982" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Ultrasound-Confirmed, Age-Specific Uterine Leiomyoma Incidence in a Cohort of Black Individuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3730804" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Risk factors for uterine fibroids: reduced risk associated with oral contraceptives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3186092" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Epidemiologic characteristics of women with uterine fibroids: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9757871" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14718211" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18226615" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The impact of race as a risk factor for symptom severity and age at diagnosis of uterine leiomyomata among affected sisters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19132395" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Uterine leiomyomata and decreased height: a common HMGA2 predisposition allele.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20693498" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Potential risk factors associated with subtypes of uterine leiomyomata.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18574205" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Menstruation in adolescents: what's normal, what's not.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10453838" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Use of oral contraceptives and uterine fibroids: results from a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1738528" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Oral contraceptive use and risk of uterine fibroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8813312" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicentre case--control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15763792" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Medical management of uterine fibroids with medroxyprogesterone acetate (Depo Provera): a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35576339" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Depot Medroxyprogesterone Acetate Use and the Development and Progression of Uterine Leiomyoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21492823" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Postpartum factors and natural fibroid regression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18971138" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : The effect of levonorgestrel intrauterine system on uterine myomas: a 1-year follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12738516" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Use of a levonorgestrel-releasing intrauterine system to treat bleeding related to uterine leiomyomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15808789" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Prenatal diethylstilbestrol (DES) exposure is associated with uterine leiomyoma development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4725959" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Rapid enlargement of a uterine fibroid after clomiphene therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1137711" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Letter: Rapid enlargement of a uterine fibroid after clomiphene therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12923156" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Risk of benign gynaecological diseases and hormonal disorders according to responsiveness to ovarian stimulation in IVF: a follow-up study of 8714 women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28497013" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Racial/ethnic disparities in environmental endocrine disrupting chemicals and women's reproductive health outcomes: epidemiological examples across the life course.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9782674" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Body fat distribution and uterine leiomyomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15824551" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Influence of body size and body fat distribution on risk of uterine leiomyomata in U.S. black women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9730029" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Risk of uterine leiomyomata among premenopausal women in relation to body size and cigarette smoking.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11159139" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Risk factors for uterine leiomyoma: a practice-based case-control study. I. African-American heritage, reproductive history, body size, and smoking.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17917603" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Anthropometric characteristics and risk of uterine leiomyoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10472866" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Diet and uterine myomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22071705" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Intake of fruit, vegetables, and carotenoids in relation to risk of uterine leiomyomata.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19955473" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : A prospective study of dairy intake and risk of uterine leiomyomata.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20200259" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Dietary glycemic index and load in relation to risk of uterine leiomyomata in the Black Women's Health Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32556077" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Dietary Fat Intake and Risk of Uterine Leiomyomata: A Prospective Ultrasound Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24598152" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Prospective study of dietary fat and risk of uterine leiomyomata.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17981250" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Lycopene and other carotenoid intake in relation to risk of uterine leiomyomata.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23493030" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Vitamin d and the risk of uterine fibroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22302692" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : 1,25-dihydroxyvitamin D3 treatment shrinks uterine leiomyoma tumors in the Eker rat model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15218005" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Risk of uterine leiomyomata in relation to tobacco, alcohol and caffeine consumption in the Black Women's Health Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8725755" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Uterine myomas and smoking. Results from an Italian study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3732529" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Constituents of cigarette smoke inhibit human granulosa cell aromatase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37148957" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : A prospective ultrasound study of cigarette smoking and uterine leiomyomata incidence and growth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23040493" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Genome-wide linkage and association analyses implicate FASN in predisposition to Uterine Leiomyomata.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23738515" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Characterization of uterine leiomyomas by whole-genome sequencing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23913526" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Exomic landscape of MED12 mutation-negative and -positive uterine leiomyomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19019355" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Risk factors for surgically removed fibroids in a large cohort of teachers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37163265" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Presence of Fibroids on Transvaginal Ultrasonography in a Community-Based, Diverse Cohort of 996 Reproductive-Age Female Participants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21068667" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Abuse in childhood and risk of uterine leiomyoma: the role of emotional support in biologic resilience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26744813" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Epidemiology of Uterine Fibroids: From Menarche to Menopause.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20627775" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : The association between self-reported major life events and the presence of uterine fibroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21150350" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Childhood abuse and fibroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23295977" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Lifetime abuse victimization and risk of uterine leiomyomata in black women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17917606" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Perceived racial discrimination and risk of uterine leiomyomata.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37163271" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Fibroid Prevalence-Still So Much to Learn.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22142874" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : An audit of indications and complications associated with elective hysterectomy at a public service hospital in South Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8829060" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Uterine leiomyomas. Racial differences in severity, symptoms and age at diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19047643" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Growth of uterine leiomyomata among premenopausal black and white women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8134065" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Hysterectomy in the United States, 1988-1990.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18357799" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Association of race, age and body mass index with gross pathology of uterine fibroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22035951" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Leiomyoma-related hospitalization and surgery: prevalence and predicted growth based on population trends.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20414843" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : New directions in the epidemiology of uterine fibroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26646122" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Association Between Patient Characteristics and Treatment Procedure Among Patients With Uterine Leiomyomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19300327" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Prevalence of uterine leiomyomas in the first trimester of pregnancy: an ultrasound-screening study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31452302" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : The association between chronic psychological stress and uterine fibroids risk: A meta-analysis of observational studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11159140" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Risk factors for uterine leiomyoma: a practice-based case-control study. II. Atherogenic risk factors and potential sources of uterine irritation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Hypertension, cardiovascular risk factors, and uterine fibroid diagnosis in midlife: Study of women’s health across the nation (SWAN)
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33035320" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Angiotensin-Converting Enzyme Inhibitors Reduce Uterine Fibroid Incidence in Hypertensive Women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33179032" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Uterine Fibroids and Hypertension: Steps Toward Understanding the Link.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28399866" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Evaluating the role of race and medication in protection of uterine fibroids by type 2 diabetes exposure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19305350" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Uterine leiomyomata in relation to insulin-like growth factor-I, insulin, and diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17241625" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Polycystic ovary syndrome and risk of uterine leiomyomata.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25901468" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Self-Reported Reproductive Tract Infections and Ultrasound Diagnosed Uterine Fibroids in African-American Women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28637238" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Chlamydia trachomatis Seroprevalence and Ultrasound-Diagnosed Uterine Fibroids in a Large Population of Young African-American Women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24268705" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Cervical neoplasia-related factors and decreased prevalence of uterine fibroids among a cohort of African American women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17090618" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Association of physical activity with development of uterine leiomyoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18304543" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Uterine fibroid treatment patterns in a population of insured women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23891629" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : The impact of uterine leiomyomas: a national survey of affected women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25901428" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Clinical practice. Uterine fibroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24033092" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : The burden of uterine fibroids for African-American women: results of a national survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17362717" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22914421" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Practice bulletin no. 128: diagnosis of abnormal uterine bleeding in reproductive-aged women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12636944" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Self-reported heavy bleeding associated with uterine leiomyomata.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24080304" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Submucosal fibroids and the relation to heavy menstrual bleeding and anemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9080227" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Leiomyoma-related bleeding: a classic hypothesis updated for the molecular era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5488038" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Endometrial changes associated with myomata of the uterus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15607866" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Uterine contractions evaluated on cine MR imaging in patients with uterine leiomyomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28836862" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Impact of uterine fibroid symptoms on health-related quality of life of US women: evidence from a cross-sectional survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23654324" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Renal impairment as a complication of uterine fibroids: a retrospective hospital-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19821668" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Venous thromboembolism as a complication of uterine fibroids: a retrospective descriptive study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21576892" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Deep-vein thrombosis is associated with large uterine fibroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22268621" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Lower extremity deep venous thrombosis with fatal pulmonary thromboembolism caused by benign pelvic space-occupying lesions--an overview.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14667888" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Uterine fibroids and gynecologic pain symptoms in a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17070199" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Uterine myomas, dyspareunia, and sexual function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21252757" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Uterine leiomyomas: individualizing the approach to a heterogeneous condition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8894327" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Elective uterine myomectomy in pregnant women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18239019" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Extrapulmonary tuberculosis in pregnancy masquerading as a degenerating leiomyoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18339376" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Fibroids and infertility: an updated systematic review of the evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28591761" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Prospective Cohort Study of Uterine Fibroids and Miscarriage Risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29016496" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Leiomyomas in Pregnancy and Spontaneous Abortion: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10421304" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Erythrocytosis and a fibroid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10215576" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Humoral hypercalcemia associated with a uterine fibroid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15599545" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Complete remission of hyperprolactinemia and erythrocytosis after hysterectomy for a uterine fibroid in a woman with a previous diagnosis of prolactin-secreting pituitary microadenoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16275226" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Abnormal uterine bleeding and underlying hemostatic disorders: report of a consensus process.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10857118" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Radiographic imaging techniques for the diagnosis of abnormal uterine bleeding.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11904599" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Accuracy of magnetic resonance imaging and transvaginal ultrasonography in the diagnosis, mapping, and measurement of uterine myomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7800322" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Transabdominal sonohysterography, transvaginal sonography, and hysteroscopy in the evaluation of submucous myomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12427815" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : The effect of pelvic MR imaging on the diagnosis and treatment of women with presumed symptomatic uterine fibroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12098104" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : I. Uterine fibroid embolization: preprocedure assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34036872" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Contrast-Enhanced Ultrasound Imaging of Uterine Disorders: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33239156" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Contrast-Enhanced Ultrasound for Monitoring Non-surgical Treatments of Uterine Fibroids: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10221611" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Abnormal uterine bleeding as a presenting sign of metastases to the uterine corpus, cervix and vagina in a breast cancer patient on tamoxifen therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26166722" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Secondary Involvement of the Adnexa and Uterine Corpus by Carcinomas of the Uterine Cervix: A Detailed Morphologic Description.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19643403" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Understanding adenomyosis: a case control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24188881" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Clinical characteristics indicating adenomyosis coexisting with leiomyomas: a retrospective, questionnaire-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15047237" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19543245" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Adenomatoid tumors of the female and male genital tracts: a clinicopathological and immunohistochemical study of 44 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12100797" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Natural history of uterine polyps and leiomyomata.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10523699" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Transient rapid growth of uterine leiomyoma in a postmenopausal woman.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20451187" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Pregnancy-related fibroid reduction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21168581" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Short-term change in growth of uterine leiomyoma: tumor growth spurts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12606893" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Why is parity protective for uterine fibroids?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7651636" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Abnormal uterine bleeding on hormone replacement: the importance of intrauterine structural abnormalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8566261" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : The effects of hormone replacement therapy on uterine fibroids in postmenopausal women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11099870" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Uterine myoma in postmenopause: a comparison between two therapeutic schedules of HRT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11755553" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Transdermal hormone replacement therapy in postmenopausal women with uterine leiomyomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11770184" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Effect of hormone replacement therapies and selective estrogen receptor modulators in postmenopausal women with uterine leiomyomas: a literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12270580" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Effect of hormone replacement therapy on uterine fibroids in postmenopausal women--a 3-year study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32474012" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : A systematic review of the psychosocial impact of fibroids before and after treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22244472" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : The estimated annual cost of uterine leiomyomata in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17012456" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Annual costs associated with diagnosis of uterine leiomyomata.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
